Informations générales (source: ClinicalTrials.gov)
Interventional
Phase 3
Gustave Roussy, Cancer Campus, Grand Paris (Voir sur ClinicalTrials)
octobre 2004
29 juin 2024
To explore in a multicenter international prospective randomized study (phase III)
whether rituximab combined with the standard French LMB chemotherapy scheme results in a
higher rate of EFS than the LMB chemotherapy scheme alone in patients older than 18 years
with Burkitt lymphoma or ALL 3.
Etablissements
| Les établissements d'Île-de-France dont les données sont issues de ClinicalTrials.gov Origine et niveau de fiabilité des données | |||||
|---|---|---|---|---|---|
| CLCC INSTITUT GUSTAVE ROUSSY | Vincent RIBRAG, MD | Contact (sur clinicalTrials) | |||
Critères
Tous
Inclusion Criteria:
- Age : 18 years or older
- Histologically or cytologically proven Burkitt lymphoma according to the WHO
classification
- WHO performance < 3
- Informed consent
- Age : 18 years or older
- Histologically or cytologically proven Burkitt lymphoma according to the WHO
classification
- WHO performance < 3
- Informed consent
- Known HIV positive infection
- Positive serology for HCV and HBV (except after vaccination)
- Patients previously treated for lymphoma
- cardiac disease that contradict anthracycline chemotherapy
- Psychological or psychiatric condition who contradict steroids therapy
- Patients with serious renal failure unrelated to the lymphoma (serum creatinin level
higher than 150 mmole/L)
- Cirrhosis or severe hepatic failure unrelated to the lymphoma
- Previous malignant disease except basal cell skin carcinoma or in situ uterine
cervix carcinoma
- Any psychological, familial, sociological or geographical condition potentially
hampering compliance with the study protocol and follow-up schedule
- Primary organ transplant or other immunosuppressive conditions Pregnancy